He had built a fintech company serving underbanked small businesses across three West African markets. The product worked: over 120,000 active users, 47% month-on-month retention in the core cohort, growing at 18% monthly on a lean cost base. He had been through a local accelerator, raised a seed round from two Africa-focused funds, and was now approaching European Series A investors.
Over four months, he had nine meetings. Eight ended with a version of the same response: “Really impressive what you’ve built, and we’d love to stay in touch as you develop the European or global angle.”
He was not receiving nos because his company was weak. He was receiving nos because he was presenting a company calibrated for one evaluation framework to investors whose pattern recognition was calibrated for a different one. His market size framing used national economic data that EU investors did not know how to benchmark. His comparable set cited companies that European investors had not seen perform at exit. His regulatory slide described the operating environment accurately but without the narrative framing that converts unfamiliarity into a thesis. His team narrative foregrounded domain expertise in markets that his audience found compelling in the abstract but difficult to price.
Three specific failures. None of them about the quality of the company.
A mutual contact introduced him to an adviser with dual-market experience. Over six weeks, he rebuilt three sections of his materials without changing a word of his operating narrative. On his next four investor meetings, he received two term sheets.
Emerging market founders are not failing to access EU and US institutional capital because their companies are weaker than local alternatives. Many are failing because the translation between home market context and investor evaluation framework is not automatic. It requires specific, learnable preparation that very few advisers explain clearly before the process begins.
Five Translation Challenges, the Structural Preparation Required, and a Preparation Checklist
1. Market size framing
EU and US institutional investors evaluate market size through a lens calibrated to markets they have seen produce exits. When a founder presents a TAM built from national GDP data, population statistics, or sector penetration rates in markets the investor has limited direct exposure to, the investor does not have a benchmarking framework to assess whether the number is credible.
Research on international valuation differences reveals a clear regional hierarchy: US pre-seed valuations lead at a median of $5.97 million, Europe follows at $3.92 million, the Middle East at $4.79 million, and Africa and Latin America at $2.60 million and $2.69 million respectively. This hierarchy is not an accurate reflection of company quality across markets; it is a reflection of investor familiarity and exit liquidity. A founder presenting in the EU needs to translate their market opportunity into terms that allow an EU investor to apply their existing benchmarking framework.
In practice, this means presenting market size in two layers: the home market opportunity sized with the assumptions made explicit, and the global or addressable extension market framed in terms the investor knows. An African fintech founder addressing SME lending is not only addressing a Nigerian or Kenyan TAM. They are addressing an underserved segment of a global SME finance market that has produced multiple exits at scale. The investor needs to see both.
2. Comparable set selection
The companies an emerging market founder naturally cites as comparables, because they are the closest operational analogues, are often companies the EU investor has not evaluated and cannot independently price. A comparable is only useful if the investor has enough context about the comparable’s trajectory to use it as a calibration reference.
The translation requirement is to build a comparable set that includes both the operationally closest company, which may be unfamiliar to the EU investor, and the structurally closest company that the EU investor does know. This typically means identifying one or two EU or US comparables that share the business model, unit economics profile, or expansion dynamic, even if the sector and geography differ, alongside the home market analogue. The investor can anchor on the familiar comparable and use the unfamiliar one to understand the specific advantages the founder’s operating context provides.
3. Team narrative
In home market fundraising, a team’s credibility is often demonstrated through domain expertise: years of experience in the sector, understanding of the regulatory environment, network density within the market. These are genuine and important signals. They are also signals that an EU investor with limited exposure to the market in question cannot independently verify or price.
The translation requirement is to re-layer the team narrative. Domain expertise should be reframed in terms of the transferable signals it demonstrates: pattern recognition in underserved markets, the ability to build and retain distribution in complex operating environments, or prior experience moving from emerging market product-market fit to international expansion. Where team members have prior experience in or education at institutions familiar to EU investors, this should be prominent. Where they do not, the narrative should build credibility through what the EU investor can verify: customer references, product metrics, and third-party validation from advisers or co-investors whose names carry weight in the EU market.
4. Regulatory risk disclosure
Operating in markets with complex, evolving, or multi-jurisdictional regulatory environments is a genuine operating advantage for founders who have built compliance architecture into their product. It is also a presentation risk if the regulatory context is described in ways that feel unfamiliar and therefore threatening to an investor who has not operated in that context.
The translation requirement is to present regulatory complexity as a competitive moat rather than a risk flag. An EU investor who reads a slide that says “subject to evolving CBN regulations and potential capital controls” without context reads it as a risk. The same investor who reads “built on a compliance-first architecture designed for a market where regulatory requirements change faster than in mature markets, creating a defensible position against less operationally experienced entrants” is reading the same fact in a framework they can evaluate positively.
5. Exit comparable choices
EU and US institutional investors price early-stage investments partly by reference to the exit landscape available to companies in that stage and geography. An emerging market founder needs to present an exit narrative that is credible within the investor’s reference framework, not just the home market’s. This typically means identifying two or three precedent transactions involving companies with similar profiles that have produced exits legible to EU or US investors, including cross-border acquisitions by global strategic buyers, not only exits on local exchanges or by local acquirers.
The median post-valuation at IPO for venture-backed European companies listing on domestic exchanges between 2015 and 2025 was approximately $45.9 million, compared to a median of $631.1 million for European companies going public in the US. This differential applies across markets: exit venue and buyer identity materially affect how investors price entry. Founders need to present exit pathways that connect to the buyer universe the EU investor can model.
Legal and structural preparation
Before approaching EU or US institutional investors, an emerging market founder needs to resolve several structural questions that, if unresolved, will stop a process at due diligence even if the initial meetings go well.
On entity structure: for founders seeking institutional capital, Delaware incorporation may be required by VCs or angel investors. The vast majority of institutional investors, venture firms, and public market players still favour Delaware for US raises, as its corporate law is familiar, predictable, and equipped for preferred stock structures, liquidation preferences, and other standard venture financing terms. For EU raises, a UK private limited company or a holding company domiciled in a major EU jurisdiction serves a similar function. The timing of restructuring matters: completing a flip, the process of establishing a new holding company above the existing operating entity, before approaching investors avoids the distraction of conducting a structural reorganisation during an active fundraising process.
On IP holding structure: EU and US investors will want to confirm that intellectual property is held in the entity they are investing in, not in a subsidiary, a related entity, or retained by a founder personally. An IP audit, confirming where all core IP is registered and ensuring it is assigned correctly into the holding entity, should be completed before due diligence begins.
On documentation standards: EU term sheets typically follow conventions developed by the British Private Equity and Venture Capital Association or local equivalents; US term sheets follow NVCA standard forms. Both differ from documentation norms in many emerging markets in the treatment of information rights, pro-rata rights, drag-along provisions, and protective provisions. A founder reviewing a term sheet for the first time without counsel experienced in the relevant jurisdiction’s venture documentation norms is likely to sign terms that are standard but whose implications they have not fully modelled. Qualified legal counsel in the target market’s jurisdiction should be engaged before the first term sheet is received, not after.
Preparation checklist
| Issue | Preparation Required | Common Mistake |
| Market size framing | Present TAM in two layers: home market with explicit assumptions; global extension market in terms familiar to target investors | Presenting only home market TAM using data sources the investor cannot independently verify |
| Comparable set | Build a three-company comparable set: closest operational analogue, closest structural EU/US analogue, most relevant exit precedent | Citing only home market comparables the investor has not seen perform at exit |
| Team narrative | Lead with transferable signals (pattern recognition, distribution-building, international expansion experience); add domain expertise as supporting evidence | Leading with domain expertise in a market the investor cannot independently price |
| Regulatory narrative | Frame regulatory complexity as a competitive moat; show compliance architecture as a defensible barrier | Presenting regulatory risk as a straightforward risk factor without operational context |
| Exit pathway | Identify two to three precedent cross-border or international transactions involving comparable profiles | Presenting only local exit options or IPO pathways on exchanges unfamiliar to the target investor |
| Entity structure | Complete flip to Delaware C-Corp or UK Ltd holding company before beginning formal process | Starting structural reorganisation during an active investor process |
| IP assignment | Complete IP audit; confirm all core IP is assigned into the investment entity | Discovering IP assignment gaps during due diligence, delaying or killing a deal |
| Documentation counsel | Engage EU or US venture counsel before receiving first term sheet | Reviewing term sheet without specialist counsel; signing standard terms without understanding their implications |
| Investor targeting | Research which EU/US funds have made investments in comparable geographies or business models; prioritise warm introductions | Approaching large generalist funds without prior emerging market portfolio context |
Disclaimer: this article is analytical commentary and does not constitute legal, regulatory, tax, or financial advice. Incorporation requirements, regulatory frameworks, and investment documentation standards vary by jurisdiction and are subject to change. Legal and tax counsel should be obtained before any cross-border structural or fundraising decision.
The Implication
The translation burden sits, at present, almost entirely with the founder. EU and US institutional investors have not, in the main, developed evaluation frameworks calibrated to companies built in markets with different regulatory environments, different liquidity profiles, and different comparable sets. They rely on the founder to do the translation work. This is a structural inefficiency in global capital allocation, and it is the primary reason why companies with strong operating metrics in high-growth markets continue to be systematically underpriced or passed over by investors whose frameworks are not equipped to evaluate them.
US investor participation in European startup deals is back on the rise, and cross-border capital flows are growing more broadly. But the infrastructure that would reduce the translation burden at scale, including standardised due diligence frameworks for emerging market companies, investor education programmes that build genuine familiarity with non-domestic operating contexts, and networks of advisers with dual-market credibility, is nascent and unevenly distributed.
Until that infrastructure matures, the translation is the founder’s problem to solve. Solving it is not a signal of weakness or an accommodation of investor insularity. It is a practical investment in access to a capital market that can fund the next stage of growth. The founders who make that investment before their process begins are the ones who convert compelling businesses into funded ones.